Ortho Clinical Diagnostics Holdings plc (OCDX): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
OCDX Stock Price Chart Interactive Chart >
OCDX Price/Volume Stats
| Current price | $21.82 | 52-week high | $22.99 |
| Prev. close | $21.33 | 52-week low | $15.14 |
| Day low | $21.42 | Volume | 548,500 |
| Day high | $22.03 | Avg. volume | 1,154,756 |
| 50-day MA | $21.07 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 4.86B |
Ortho Clinical Diagnostics Holdings plc (OCDX) Company Bio
Ortho Clinical Diagnostics Holdings plc operates as a holding company. The Company, through its subsidiaries, provides vitro diagnostics products and services to the global clinical laboratory and immunohematology communities. Ortho Clinical Diagnostics Holdings serves customers worldwide.
Latest OCDX News From Around the Web
Below are the latest news stories about Ortho Clinical Diagnostics Holdings plc that investors may wish to consider to help them evaluate OCDX as an investment opportunity.
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in CanadaOrtho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in Canada. |
Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the “Investors” porti |
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho''s Critical Care Blood Testing MenuRARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world''s largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho''s VITROS® Critical Care menu, |
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing MenuOrtho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.* |
Blood Transfusion Diagnostics Market to See Massive Growth by 2031 | Grifols S.A., Immucor Inc., Ortho Clinical Diagnostics, Diamond Diagnostics, Abbott LaboratoriesThe latest insightSLICE research report published on Blood Transfusion Diagnostics promises to cede reliable and clarifying insights appertaining to the real time scenario trajectory concerning the market arena during the speculated forecast period of 2021-2031. Setting forth the risks and opportunities |
OCDX Price Returns
| 1-mo | 0.32% |
| 3-mo | 10.09% |
| 6-mo | 35.53% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...